Impact of line probe assay-based molecular testing on individualized treatment in patients with rifampicin-resistant tuberculosis: data from the prospective INNOVA4TB cohort study in Ukraine

Dudnyk, A.; Hempel, M.; Lytvyniuk, O.; Liudkevych, H.; Matsera, V.; Nikitchenko, T.; Blyzniuk, S.; Molina-Moya, B.; Preyer, R.; Domínguez, J.

Домівка
→
Кафедра фтизіатрії з курсом клінічної імунології та алергології
→
Наукові публікації каф. фтизіатрії
→
Перегляд матеріалів

Impact of line probe assay-based molecular testing on individualized treatment in patients with rifampicin-resistant tuberculosis: data from the prospective INNOVA4TB cohort study in Ukraine

Dudnyk, A.; Hempel, M.; Lytvyniuk, O.; Liudkevych, H.; Matsera, V.; Nikitchenko, T.; Blyzniuk, S.; Molina-Moya, B.; Preyer, R.; Domínguez, J.

URI: https://dspace.vnmu.edu.ua/123456789/7130

Дата: 2024

Короткий опис (реферат):

Ukraine remains a high World Health Organization priority country for drug-resistant tuberculosis (TB). Rifampicin-resistant TB (RR-TB) has a more protracted, more complicated, and more expensive treatment. In 2021, Ukraine reported 4025 RR-TB cases – 5.4 times more (751) than all 30 European Union/ European Economic Area countries together. The objective of the study was to determine the diagnostic accuracy of line probe assay (LPA), AID Autoimmun Diagnostika GmbH, for detecting resistance to anti-TB drugs and its clinical application for selecting treatment regimens.

Показати повний опис матеріалу